Abstract #1999
Prediction of Treatment Response in Pancreatic Cancer Using EPR Oxygen Imaging
Shingo Matsumoto 1,2 , Keita Saito 1 , Jeeva P Munasinghe 3 , Nallathamby Devasahayam 1 , James B Mitchell 1 , Robert J Gillies 4 , and Murali C Krishna 1
1
Radiation Biology Branch, National Cancer
Institute, NIH, Bethesda, MD, United States,
2
Hokkaido
University, Sapporo, Hokkaido, Japan,
3
Mouse
Imaging Facility, NINDS, NIH, Bethesda, MD, United
States,
4
Imaging
and Metabolism, H. Lee Moffitt Cancer Center and
Research Institute, Tampa, FL, United States
Pancreatic cancer is a malignant neoplasm with an
extremely poor prognosis. The TH-302 is a kind of drugs
known as hypoxia-activated prodrug (HAP), which
activated under hypoxia (low concentration of oxygen)
and exhibits anti-tumor effect. A question derived is
how clinicians select patients who receive most benefit
from treatment with this hypoxia targeting new drug.
Electron paramagnetic resonance imaging (EPRI) can
non-invasively provide 3D absolute oxygen images. Here,
we investigated if the EPR oxygen imaging can predict
treatment benefit of oxygen dependent or independent
therapies in three different pancreatic cancer
xenografts.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here